SequelSEC

Dyne Therapeutics, Inc. DYN

Pharmaceutical Preparations · CIK 0001818794 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$181.66M
Fiscal year ended 2026-06-30
Free cash flow
-$131.80M
Fiscal year ended 2026-06-30

Dyne Therapeutics, Inc. (DYN) reported net income of -$178.56M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Dyne Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Dyne Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$181.66MUnavailable-$116.13M-$113.89MUnavailableUnavailable-$97.11M-$105.57MUnavailableUnavailable
Net income-$178.56MUnavailable-$111.96M-$108.04MUnavailableUnavailable-$89.54M-$97.12MUnavailableUnavailable
Research & development$152.17MUnavailable$95.43M$97.22MUnavailableUnavailable$81.80M$92.80MUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.08Unavailable$-0.73$-0.76UnavailableUnavailable$-0.88$-0.96UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$29.49MUnavailable$20.70M$16.67MUnavailableUnavailable$15.30M$12.86MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Dyne Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$676.11MUnavailable$893.37M$573.61MUnavailableUnavailable$435.45M$532.16MUnavailableUnavailable
Total assets$994.01MUnavailable$1.19B$867.06MUnavailableUnavailable$691.23M$768.84MUnavailableUnavailable
Current assets$937.89MUnavailable$1.13B$806.26MUnavailableUnavailable$659.28M$736.39MUnavailableUnavailable
Total liabilities$291.86MUnavailable$214.83M$175.28MUnavailableUnavailable$61.40M$63.30MUnavailableUnavailable
Current liabilities$78.03MUnavailable$50.62M$59.85MUnavailableUnavailable$42.26M$43.26MUnavailableUnavailable
Total equity incl. NCI$702.15MUnavailable$972.13M$691.78MUnavailableUnavailable$629.84M$705.54MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$199.33MUnavailable$148.92M$99.15MUnavailableUnavailable$0UnavailableUnavailableUnavailable
Accounts payable$12.15MUnavailable$8.08M$12.06MUnavailableUnavailable$6.56M$6.16MUnavailableUnavailable

Cash flow

Dyne Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$130.29MUnavailable-$111.83M-$90.78MUnavailableUnavailable-$84.34M-$74.63MUnavailableUnavailable
Capital expenditures$1.51MUnavailable$484.00K$395.00KUnavailableUnavailable$1.08M$253.00KUnavailableUnavailable
Investing cash flow-$4.80MUnavailable$982.00K-$37.96MUnavailableUnavailable-$16.01M-$19.40MUnavailableUnavailable
Financing cash flow$58.11MUnavailable$430.96M$217.33MUnavailableUnavailable$3.64M$18.01MUnavailableUnavailable
Net change in cash-$76.97MUnavailable$320.12M$88.58MUnavailableUnavailable-$96.71M-$76.02MUnavailableUnavailable
Stock-based compensation$14.98MUnavailable$11.23M$11.08MUnavailableUnavailable$10.48M$8.74MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$600.00KUnavailable$521.00K$500.00KUnavailableUnavailable$450.00K$400.00KUnavailableUnavailable

Derived

Dyne Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$131.80MUnavailable-$112.32M-$91.17MUnavailableUnavailable-$85.41M-$74.88MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio12.02xUnavailable22.25x13.47xUnavailableUnavailable15.60x17.02xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.28xUnavailable0.15x0.14xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DYN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-07-28View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.